Joy For SMA Patients As NICE And Biogen Break Spinraza Deadlock
Between 600-1,200 people in England and Wales may be able to get Spinraza now that after 17 months of negotiations "appropriate flexibility" has led to an access agreement.
You may also be interested in...
Reports of patient deaths could raise questions around safety for Novartis's gene therapy Zolgensma which is expected to get the green light imminently from the FDA.
Podcast: Living In China's Coronavirus Lockdown, Novartis and England's 'Public Health' Alliance; Biogen's Moment of Truth Approaches
After a strong start in the US, Novartis is now ready to take on Bayer's wet age-related macular degeneration blockbuster Eylea in Europe.